Breaking News

Sulzer Confirms Merger Talks With Dresser-Rand
Tweet TWEET

Aegerion Pharmaceuticals Grants Stock Options Under Inducement Program

Aegerion Pharmaceuticals Grants Stock Options Under Inducement Program

CAMBRIDGE, Mass., Feb. 7, 2013 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals,
Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development
and commercialization of innovative, life-altering therapies for patients with
debilitating and often fatal rare diseases, today announced that on February
1, 2013, Aegerion granted stock options to purchase an aggregate of 78,500
shares of common stock to six new employees under the inducement stock option
program described below. Each stock option has an exercise price per share
equal to $27.83, the closing price of Aegerion's common stock on the grant
date; vests in equal monthly installments over four years; has a ten year
term; and is subject to the terms and conditions of Aegerion's Inducement
Award Stock Option Plan, and the terms and conditions of a stock option
agreement covering the grant.

As Aegerion previously announced, in support of the company's build of its
U.S. commercial organization and international expansion, the Compensation
Committee of the Company's Board of Directors approved the reservation of
1,000,000 shares of common stock to be used exclusively for the grant of
non-qualified stock options to individuals who were not previously an employee
or non-employee director of Aegerion (or following a bona fide period of
non-employment), as an inducement new hire stock option award material to an
individual's entry into employment within the meaning of Rule 5635(c)(4) of
the NASDAQ Listing Rules (Inducement Stock Options).  

About Aegerion Pharmaceuticals

Aegerion Pharmaceuticals is a biopharmaceutical company dedicated to the
development and commercialization of innovative, life-altering therapies for
patients with debilitating, often fatal, rare diseases. For more information
about the company, please visit www.aegerion.com.

The Aegerion Pharmaceuticals, Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=16441

CONTACT: Aegerion Pharmaceuticals, Inc.
         Amanda Murphy
         Manager, Investor Relations
         (857) 242-5024

Aegerion Pharmaceuticals, Inc. Logo
 
Press spacebar to pause and continue. Press esc to stop.